Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
Summit Therapeutics (SMMT) Stock Price & Analysis
296 Followers
SMMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.50 - $5.39
Previous Close$4.8
Volume1.16M
Average Volume (3M)2.28M
Market Cap
$3.33B
Enterprise Value$3.29B
Total Cash (Recent Filing)$186.24M
Total Debt (Recent Filing)$106.10M
Price to Earnings (P/E)-29.0
Beta-1.71
Next Earnings
Aug 07, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding701,979,596
10 Day Avg. Volume2,705,343
30 Day Avg. Volume2,278,042
Standard Deviation0.61
R-Squared0.00992
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)43.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-41.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.63K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.79
Forecast
1Y Price Target
$7.50Price Target Upside58.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Summit Therapeutics News
PremiumCompany Announcements
Summit Therapeutics Appoints Biotech Veteran to Board
PremiumCompany Announcements
Summit Therapeutics Announces Major Leadership Restructuring
Ownership Overview
82.79% Insiders
2.45% Mutual Funds
3.17% Other Institutional Investors
11.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $1.50 and its highest was $5.39 in the past 12 months.
What is Summit Therapeutics’s market cap?
Currently, no data Available
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 85 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on May 01, 2024. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 701,979,600 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went up 19.593%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Among the largest hedge funds holding Summit Therapeutics’s share is Robert Bender&Associates. It holds Summit Therapeutics’s shares valued at 63K.
---
Summit Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (58.23% Upside)
$7.50 (58.23% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $786.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.06%
12-Months-Change
Fundamentals
Return on Equity
-130.63%
Trailing 12-Months
Asset Growth
-30.65%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
---
SMMT Earnings Call
Q1 2024
0:00 / 0:00
---
SMMT Stock 12 Month Forecast
Average Price Target
$7.50
▲(58.23% Upside)
Technical Analysis
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+18.03%
reiterated a buy rating 13 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.03% per trade.
---